Á lódáil...
Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
Treatment with the chemotherapeutic agent bevacizumab, a humanized mAb that neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage. The risk factors and clinical outcomes of renal adverse events are not well understood. We performed a systematic review and meta-anal...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
American Society of Nephrology
2010
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2938590/ https://ncbi.nlm.nih.gov/pubmed/20538785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2010020167 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|